Key result
Olezarsen gains FDA approval to reduce triglycerides and acute pancreatitis risk in severe hypertriglyceridemia.
Why the study?
Does olezarsen reduce triglyceride levels and the risk of acute pancreatitis in adults with severe hypertriglyceridemia?
Does olezarsen reduce triglyceride levels and the risk of acute pancreatitis in adults with severe hypertriglyceridemia?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“As a physician, I have seen firsthand how challenging it can be for patients with sHTG to lower their triglycerides below 500 mg/dL, despite background lipid-lowering therapies and lifestyle changes, which leaves them at risk of a devastating and potentially life-threatening acute pancreatitis attack. TRYNGOLZA is a transformational new therapy that showed unprecedented, clinically meaningful outcomes for sHTG, with the potential to redefine the treatment paradigm.”
“Acute pancreatitis is a painful and potentially life-threatening condition that often requires urgent hospitalisation. People with triglyceride levels above 10 mmol/L have a four times greater risk of acute pancreatitis compared to those with ideal low levels, and this risk increases progressively as triglyceride levels rise. According to EAS/ESC guidelines, triglyceride levels above 10 mmol/L warrant urgent intervention to prevent acute pancreatitis.”
“These results add to the collective body of evidence for olezarsen, showing the reduction of acute pancreatitis risk in severe hypertriglyceridemia. As rates of acute pancreatitis continue to increase, olezarsen has the potential to be an important part of a preventative approach to disease management in at-risk patients.”
The FDA has approved olezarsen, an apoC-III-directed antisense oligonucleotide, for the treatment of severe hypertriglyceridemia to reduce triglycerides and acute pancreatitis risk.
The FDA has approved olezarsen (Tryngolza – Ionis), a subcutaneously injected apolipoprotein C-III (apoC-III)-directed antisense oligonucleotide, to reduce triglyceride levels and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. Olezarsen and the apoC-III-directed small interfering RNA plozasiran (Redemplo) were approved earlier to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS).
No takes yet. Share an insight, caveat, or question.
A 2026 study studied Severe hypertriglyceridemia. Olezarsen was evaluated on Triglyceride levels and risk of acute pancreatitis. The FDA approved olezarsen, a subcutaneous apoC-III-directed antisense oligonucleotide, to reduce triglyceride levels and acute pancreatitis risk in adults with severe hypertriglyceridemia.
Synapse has enriched 10 related papers. Consider them for comparative context: